NRG ONCOLOGY NETWORK GROUP OPERATIONS CENTER

NRG 肿瘤网络集团运营中心

• 批准号: 9247148
• 负责人: WALTER J. CURRAN
• 金额: $ 1347.56万
• 依托单位: NRG ONCOLOGY FOUNDATION, INC.
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-04-17 至 2019-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9247148
• 关键词: Adult; Biological Markers; Brain Neoplasms; Cancer Control; Cancer Control Research; Cancer Survivorship; Caring; Clinical Research; Clinical Trials; Colorectal; Decision Making; Development; Developmental Therapeutics Program; Diagnostic; Disease; Endometrial Carcinoma; Enrollment; Gender; Gynecologic Oncology Group; Head and Neck Cancer; Image; Information Technology; Investigation; Investigational Therapies; Knowledge; Leadership; Malignant Female Reproductive System Neoplasm; Malignant Neoplasms; Malignant neoplasm of cervix uteri; Malignant neoplasm of gastrointestinal tract; Malignant neoplasm of lung; Malignant neoplasm of ovary; Malignant neoplasm of prostate; Medical Technology; Mission; Modeling; Modernization; Multi-Institutional Clinical Trial; National Clinical Trials Network; National Surgical Adjuvant Breast and Bowel Project; Operative Surgical Procedures; Outcomes Research; Pathway interactions; Patient Care; Patient-Focused Outcomes; Patients; Phase; Phase II/III Trial; Process; Protocols documentation; Radiation Oncology; Radiation Therapy Oncology Group; Randomized; Recording of previous events; Regulation; Research; Resources; Risk stratification; Site; Systemic Therapy; Technology; Testing; Therapeutic; Therapeutic Human Experimentation; Therapeutics Committee; Translational Research; Urogenital Cancer; Vision; base; biobank; cancer imaging; cancer prevention; clinical decision-making; data management; design; improved; innovation; knowledge base; malignant breast neoplasm; novel; oncology; operation; phase III trial; programs; public health relevance; success; tumor

DESCRIPTION (provided by applicant): NRG Oncology is a newly constituted NCI National Clinical Trials Network (NCTN) network group created through the coordinated efforts of the National Surgical Adjuvant Breast and Bowel Project (NSABP), the Radiation Therapy Oncology Group (RTOG), and the Gynecologic Oncology Group (GOG) with a primary vision of improving the lives of adult patients with localized or locally advanced malignancies through the conduct of high quality NCI-supported multi-institutional clinical trials. NRG Oncology (or NRG) has leveraged the tremendous resources, leadership, membership, and history of practice-defining research of the three legacy groups to create a modern clinical and translational research organization with the capability to execute clinical and translational research trials for adult patients with common and rare malignancies in the following disease sites: Gynecologic Cancer (including Ovarian, Cervix and Endometrial Cancer); Brain Tumors (Primary and Secondary); Breast Cancer; Gastrointestinal Cancers (Colorectal and Non-Colorectal Cancers); Genitourinary Cancer; Head and Neck Cancer; and Lung Cancer. NRG will be the leading network group defining new standards of care and scientific paradigms for several of these disease sites. For these seven cancer disease sites, NRG will primarily conduct trials for patients with early or intermediate stage cancers testing innovative diagnostic and therapeutic approaches, including novel imaging, radiation oncology, and surgical approaches; the integration of novel systemic agents or classes of systemic agents with optimized loco-regional therapies and existing systemic therapies, and the use of biomarker- and biologic pathway-defined approaches to risk stratification, investigational therapy assignment, and clinical trial decision-making. The group has seven scientific core committees and four integrated committees which provide both scientific support and generate protocols: Developmental Therapeutics (DT), Translational Science, Patient-Centered Outcomes Research, and Cancer Prevention and Control Committees. NRG's DT Committee builds on the GOG DT Committee's success in enrolling over 500 patients/year on early phase trials leading to phase III trials. The NRG Operations Center is fully aligned with NRG Oncology Statistical and Data Management Center (SDMC) and the NRG Biorepositories and will be fully compliant with all NCI regulations and proactive in improving the efficiency and quality of its research. The group will serve as a scientific resource for other NCTN network groups for radiation oncology innovation through its Center for Innovative Radiation Oncology (CIRO).

描述（由申请人提供）：NRG 肿瘤学是新成立的 NCI 国家临床试验网络 (NCTN) 网络小组，是通过国家外科辅助乳腺和肠道项目 (NSABP)、放射治疗肿瘤学小组 (RTOG)、妇科肿瘤组 (GOG) 的主要愿景是通过高质量的治疗来改善患有局部或局部晚期恶性肿瘤的成年患者的生活NCI 支持的多机构临床试验。 NRG Oncology（或 NRG）利用三个传统团体的巨大资源、领导力、成员资格和实践定义研究历史，创建了一个现代化的临床和转化研究组织，有能力为成年患者执行临床和转化研究试验患有以下疾病部位的常见和罕见恶性肿瘤：妇科癌症（包括卵巢癌、子宫颈癌和子宫内膜癌）；脑肿瘤（原发性和继发性）；乳腺癌;胃肠道癌（结直肠癌和非结直肠癌）；泌尿生殖系统癌症；头颈癌；和肺癌。 NRG 将成为领先的网络团体，为其中一些疾病场所定义新的护理标准和科学范例。对于这七个癌症疾病部位，NRG将主要针对早期或中期癌症患者进行试验，测试创新的诊断和治疗方法，包括新颖的影像学、放射肿瘤学和手术方法；将新型全身药物或一类全身药物与优化的局部治疗和现有的全身治疗相结合，以及使用生物标志物和生物途径定义的方法进行风险分层、研究性治疗分配和临床试验决策。该小组拥有七个科学核心委员会和四个综合委员会，提供科学支持并制定协议：发育治疗（DT）委员会、转化科学委员会、以患者为中心的结果研究委员会以及癌症预防和控制委员会。 NRG 的 DT 委员会建立在 GOG DT 委员会每年招募超过 500 名患者进行早期试验并最终进入 III 期试验的成功基础上。 NRG 运营中心与 NRG 肿瘤统计和数据管理中心 (SDMC) 以及 NRG 生物样本库完全一致，并将完全遵守所有 NCI 法规，并积极提高其研究的效率和质量。该小组将通过其创新放射肿瘤学中心 (CIRO) 为其他 NCTN 网络团体提供放射肿瘤学创新的科学资源。